Clinical trial NCT02058875 - References

Cardiovascular Disease — Cardiovascular Risk Following Conversion to Full Dose Myfortic® and Neoral® Two-hour Post Level Monitoring

Citation(s)

•   Barama A, Sepandj F, Gough J, McKenna R
  Correlation between Neoral 2 hours post-dose levels and histologic findings on surveillance biopsies. Transplant Proc. 2004 Mar;36(2 Suppl):465S-467S.
•   Behrend M, Braun F
  Enteric-coated mycophenolate sodium: tolerability profile compared with mycophenolate mofetil. Drugs. 2005;65(8):1037-50. Review.
•   Bolin P Jr, Gohh R, Kandaswamy R, Shihab FS, Wiland A, Akhlaghi F, Melancon K
  Mycophenolic acid in kidney transplant patients with diabetes mellitus: does the formulation matter? Transplant Rev (Orlando). 2011 Jul;25(3):117-23. doi: 10.1016/j.trre.2010.12.003. Review.
•   Carstens J
  Three-years experience with Neoral C2 monitoring adjusted to a target range of 500-600 ng/ml in long-term renal transplant recipients receiving dual immunosuppressive therapy. Scand J Urol Nephrol. 2008;42(3):286-92. doi: 10.1080/00365590701748039.
•   Cibrik D, Meier-Kriesche HU, Bresnahan B, Wu YM, Klintmalm G, Kew CE, Kuo PC, Whelchel J, Cohen D, Baliga P, Akalin E, Benedetti E, Wright F, Lieberman B, Ulbricht B, Jensik S; Myfortic-US01 Renal Transplant Study Group
  . Renal function with cyclosporine C2 monitoring, enteric-coated mycophenolate sodium and basiliximab: a 12-month randomized trial in renal transplant recipients. Clin Transplant. 2007 Mar-Apr;21(2):192-201.
•   Citterio F
  Evolution of the therapeutic drug monitoring of cyclosporine. Transplant Proc. 2004 Mar;36(2 Suppl):420S-425S. Review.
•   Cuero C, Delgado E, de González M, Medina C, Vernaza A, Moscoso J
  [C0 vs C2 levels and their implications in kidney transplantation]. Rev Med Panama. 2002;27:30-3. Spanish.
•   D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, Kannel WB
  General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008 Feb 12;117(6):743-53. doi: 10.1161/CIRCULATIONAHA.107.699579.
•   Domínguez J, Fuenzalida D, Norambuena R, Pais E, Cortes Monroy G, Llanos R
  C2 monitoring of cyclosporine in stable renal transplant patients results in lower costs and improved renal function. Transplant Proc. 2005 Apr;37(3):1583-5.
•   Ducloux D, Kazory A, Chalopin JM
  Predicting coronary heart disease in renal transplant recipients: a prospective study. Kidney Int. 2004 Jul;66(1):441-7.
•   Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, Couture P, Dufour R, Fodor G, Francis GA, Grover S, Gupta M, Hegele RA, Lau DC, Leiter L, Lewis GF, Lonn E, Mancini GB, Ng D, Pearson GJ, Sniderman A, Stone JA, Ur E
  2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol. 2009 Oct;25(10):567-79. Review.
•   Gozdowska J, Urbanowicz AL, Galazka Z, Chmura A, Durlik M
  Tolerance of enteric-coated mycophenolate sodium in combination with calcineurin inhibitor in kidney transplant recipients: Polish experience. Transplant Proc. 2011 Oct;43(8):2946-9. doi: 10.1016/j.transproceed.2011.08.056.
•   Hernández D, Moreso F
  Has patient survival following renal transplantation improved in the era of modern immunosuppression? Nefrologia. 2013;33(2):171-80. doi: 10.3265/Nefrologia.pre2012.Nov.11743. Review. English, Spanish.
•   Holdaas H, Fellström B, Jardine AG, Holme I, Nyberg G, Fauchald P, Grönhagen-Riska C, Madsen S, Neumayer HH, Cole E, Maes B, Ambühl P, Olsson AG, Hartmann A, Solbu DO, Pedersen TR; Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators
  . Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003 Jun 14;361(9374):2024-31.
•   Hoorn EJ, Walsh SB, McCormick JA, Fürstenberg A, Yang CL, Roeschel T, Paliege A, Howie AJ, Conley J, Bachmann S, Unwin RJ, Ellison DH
  The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension. Nat Med. 2011 Oct 2;17(10):1304-9. doi: 10.1038/nm.2497.
•   Israni AK, Snyder JJ, Skeans MA, Peng Y, Maclean JR, Weinhandl ED, Kasiske BL; PORT Investigators
  . Predicting coronary heart disease after kidney transplantation: Patient Outcomes in Renal Transplantation (PORT) Study. Am J Transplant. 2010 Feb;10(2):338-53. doi: 10.1111/j.1600-6143.2009.02949.x.
•   Jardine AG, Fellström B, Logan JO, Cole E, Nyberg G, Grönhagen-Riska C, Madsen S, Neumayer HH, Maes B, Ambühl P, Olsson AG, Pedersen T, Holdaas H
  Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study. Am J Kidney Dis. 2005 Sep;46(3):529-36.
•   Jiang S, Tang Q, Rong R, Tang L, Xu M, Lu J, Jia Y, Ooi Y, Hou J, Guo J, Yang B, Zhu T
  Mycophenolate mofetil inhibits macrophage infiltration and kidney fibrosis in long-term ischemia-reperfusion injury. Eur J Pharmacol. 2012 Aug 5;688(1-3):56-61. doi: 10.1016/j.ejphar.2012.05.001.
•   Kahan BD, Podbielski J, Childs B
  The impact of conversion from mycophenolate mofetil to mycophenolate sodium among renal transplant recipients on a sirolimus-based regimen. Transplant Proc. 2008 Jun;40(5):1429-34. doi: 10.1016/j.transproceed.2008.04.009.
•   Kamar N, Rostaing L, Cassuto E, Villemain F, Moal MC, Ladrière M, Barrou B, Ducloux D, Chaouche K, Quéré S, Di Giambattista F, Be F
  A multicenter, randomized trial of increased mycophenolic acid dose using enteric-coated mycophenolate sodium with reduced tacrolimus exposure in maintenance kidney transplant recipients. Clin Nephrol. 2012 Feb;77(2):126-36. doi: 10.5414/CN107227.
•   Kasiske BL, Chakkera HA, Roel J
  Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol. 2000 Sep;11(9):1735-43.
•   Kiberd B, Panek R
  Cardiovascular outcomes in the outpatient kidney transplant clinic: the Framingham risk score revisited. Clin J Am Soc Nephrol. 2008 May;3(3):822-8. doi: 10.2215/CJN.00030108.
•   Kockx M, Jessup W, Kritharides L
  Cyclosporin A and atherosclerosis--cellular pathways in atherogenesis. Pharmacol Ther. 2010 Oct;128(1):106-18. doi: 10.1016/j.pharmthera.2010.06.001. Review.
•   Langone AJ, Chan L, Bolin P, Cooper M
  Enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients experiencing gastrointestinal intolerance: a multicenter, double-blind, randomized study. Transplantation. 2011 Feb 27;91(4):470-8. doi: 10.1097/TP.0b013e318205568c.
•   Luft FC
  How calcineurin inhibitors cause hypertension. Nephrol Dial Transplant. 2012 Feb;27(2):473-5. doi: 10.1093/ndt/gfr679.
•   Meneses Rde P, Kotsifas CH
  Benefits of conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in pediatric renal transplant patients with stable graft function. Pediatr Transplant. 2009 Mar;13(2):188-93. doi: 10.1111/j.1399-3046.2008.00977.x.
•   Nankivell BJ, Chapman JR
  Chronic allograft nephropathy: current concepts and future directions. Transplantation. 2006 Mar 15;81(5):643-54. Review.
•   Nart A, Sipahi S, Aykas A, Uslu A, Hoscoskun C, Toz H
  Efficacy and safety of enteric-coated mycophenolate sodium in de novo and maintenance renal transplant patients. Transplant Proc. 2008 Jan-Feb;40(1):189-92. doi: 10.1016/j.transproceed.2007.11.066.
•   Nashan B, Ivens K, Suwelack B, Arns W, Abbud Filho M; myPROMS DE02 Study Group
  ; LA01 Study Group.. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant patients: preliminary results from the myfortic prospective multicenter study. Transplant Proc. 2004 Mar;36(2 Suppl):521S-523S.
•   Nemati E, Einollahi B, Taheri S, Moghani-Lankarani M, Kalantar E, Simforoosh N, Nafar M, Saadat AR
  Cyclosporine trough (C0) and 2-hour postdose (C2) levels: which one is a predictor of graft loss? Transplant Proc. 2007 May;39(4):1223-4.
•   Ojo AO
  Cardiovascular complications after renal transplantation and their prevention. Transplantation. 2006 Sep 15;82(5):603-11. Review.
•   Ponticelli C, Cucchiari D, Graziani G
  Hypertension in kidney transplant recipients. Transpl Int. 2011 Jun;24(6):523-33. doi: 10.1111/j.1432-2277.2011.01242.x. Review.
•   Ponticelli C
  Generic cyclosporine: a word of caution. J Nephrol. 2004 Nov-Dec;17 Suppl 8:S20-4. Review.
•   Sabbatini M, Capone D, Gallo R, Pisani A, Polichetti G, Tarantino G, Gentile A, Rotaia E, Federico S
  EC-MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF-related gastrointestinal side-effects. Fundam Clin Pharmacol. 2009 Oct;23(5):617-24. doi: 10.1111/j.1472-8206.2009.00711.x.
•   Silver SA, Huang M, Nash MM, Prasad GV
  Framingham risk score and novel cardiovascular risk factors underpredict major adverse cardiac events in kidney transplant recipients. Transplantation. 2011 Jul 27;92(2):183-9. doi: 10.1097/TP.0b013e31821f303f.
•   Soveri I, Holdaas H, Jardine A, Gimpelewicz C, Staffler B, Fellström B
  Renal transplant dysfunction--importance quantified in comparison with traditional risk factors for cardiovascular disease and mortality. Nephrol Dial Transplant. 2006 Aug;21(8):2282-9.
•   Soveri I, Holme I, Holdaas H, Budde K, Jardine AG, Fellström B
  A cardiovascular risk calculator for renal transplant recipients. Transplantation. 2012 Jul 15;94(1):57-62. doi: 10.1097/TP.0b013e3182516cdc.
•   Soveri I, Snyder J, Holdaas H, Holme I, Jardine AG, L'Italien GJ, Fellström B
  The external validation of the cardiovascular risk equation for renal transplant recipients: applications to BENEFIT and BENEFIT-EXT trials. Transplantation. 2013 Jan 15;95(1):142-7. doi: 10.1097/TP.0b013e31827722c9.
•   Suwelack B, Gerhardt U, Hohage H
  Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. Am J Transplant. 2004 Apr;4(4):655-62.
•   Tang SC, Chan KW, Tang CS, Lam MF, Leung CY, Tse KC, Li CS, Ho YW, Tong MK, Lai KN, Chan TM; Hong Kong Nephrology Study Group
  . Conversion of ciclosporin A to tacrolimus in kidney transplant recipients with chronic allograft nephropathy. Nephrol Dial Transplant. 2006 Nov;21(11):3243-51.
•   Tedesco D, Haragsim L
  Cyclosporine: a review. J Transplant. 2012;2012:230386. doi: 10.1155/2012/230386.
•   Textor SC, Taler SJ, Canzanello VJ, Schwartz L, Augustine JE
  Posttransplantation hypertension related to calcineurin inhibitors. Liver Transpl. 2000 Sep;6(5):521-30. Review.
•   Watt KD
  Metabolic syndrome: is immunosuppression to blame? Liver Transpl. 2011 Nov;17 Suppl 3:S38-42. doi: 10.1002/lt.22386. Review.
•   White SL, Polkinghorne KR, Atkins RC, Chadban SJ
  Comparison of the prevalence and mortality risk of CKD in Australia using the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) Study GFR estimating equations: the AusDiab (Australian Diabetes, Obesity and Lifestyle) Study. Am J Kidney Dis. 2010 Apr;55(4):660-70. doi: 10.1053/j.ajkd.2009.12.011.

Comparisons Of Inflammatory Biomarkers And Cardiovascular Risk Scores Before And After Conversion To Full Dose Myfortic® Using Two Hour Neoral® Monitoring.

Details for clinical trial NCT02058875